Therefore CD19- and CD20-targeting antibodies might complement each other in the treatment of patients with B-cell lymphomas, as CD19 might compensate for CD20-low/-negative settings and vice versa. The gene discussed is MS4A1; the disease is B-cell non-Hodgkin lymphoma.